Syndax Pharmaceuticals, Inc. (SNDX) 株式分析

企業概要

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the development of therapeutic agents specifically designed for the treatment of cancer. The company operates within the Healthcare sector, functioning as a specialized entity in the Biotechnology industry where innovation and clinical trial success are primary drivers of value. Syndax currently maintains a market capitalization of $2.17B, generates an annual revenue of $172.35M, and employs a workforce of 298 individuals. These financial metrics indicate that the company possesses a significant valuation relative to its current revenue generation, suggesting that the market prices the enterprise based on future potential rather than existing cash flow, a common characteristic for biotechnology firms in the commercial-stage phase where asset development is prioritized over immediate profitability.

財務健全性

Syndax reported a trailing twelve-month revenue of $172.35M, yet it recorded a net income of -$285,422,016 and an EBITDA of -$273,478,016 during the same period. The substantial gap between the positive revenue figure and the heavily negative net income reveals a cost structure where research, development, and operational expenditures significantly exceed the income generated from sales, which is typical for companies investing heavily in clinical pipelines. The company's free cash flow stands at -$210,053,120, indicating a continuous cash burn that limits immediate financial flexibility and necessitates reliance on external capital sources or internal reserves to fund ongoing operations. When analyzing profitability efficiency, the gross margin is recorded at -54.2%, the operating margin at -91.6%, and the profit margin at -165.6%, figures that collectively demonstrate that the cost of goods sold and operating expenses are drastically outpacing revenue, resulting in a loss on every dollar of sales. Regarding balance sheet leverage, Syndax holds $413.69M in cash against $345.43M in debt, resulting in a debt-to-equity ratio of 534.48, which suggests a highly leveraged position where liabilities far outweigh shareholder equity, yet the substantial cash balance provides a critical buffer against short-term obligations. The current ratio is 4.40, a metric that indicates strong short-term liquidity as the company holds more than four times the value of its current assets compared to its current liabilities. Furthermore, the return on equity is -161.8% and the return on assets is -27.3%, metrics that reveal that management's effectiveness in generating profit from shareholder capital and total assets is currently negative, reflecting the inherent challenges of scaling a biotechnology business before achieving commercial milestone success.

バリュエーション評価

Syndax presents a trailing P/E ratio of N/A due to the absence of positive earnings, while the forward P/E is listed at -41.12, a divergence that implies the market is pricing in significant future earnings improvements expected to turn the current losses into profitability over the forecast period. The price-to-book ratio stands at 33.23, indicating that the market values the company at more than thirty-three times its net asset value, which suggests a high premium assigned to the company's intellectual property and future drug candidates rather than its tangible book value. Alternative valuation metrics further illustrate this disparity, with a price-to-sales ratio of 12.57 and an EV/EBITDA of -7.67, suggesting that investors are valuing the firm based on revenue potential and market expectations of future cash flow generation rather than current profitability or earnings yield. In terms of trading range, the 52-week high is $25.59 and the 52-week low is $8.58, meaning the current market price sits within this volatility band, reflecting the speculative nature of the stock price movements typical for high-growth biotech firms. The beta value is 0.41, which indicates that the stock price volatility is less than the broader market, suggesting that SNDX moves with lower sensitivity to general market fluctuations compared to the S&P 500, although this lower beta does not mitigate the specific risks associated with the company's clinical development pipeline.

Growth & Income

Syndax has experienced a revenue growth year-over-year of 794.9%, while the earnings growth year-over-year is N/A due to the company's continued negative earnings position. The absence of earnings growth while revenue expands rapidly implies that the company is prioritizing market expansion and revenue scaling over immediate profitability, a strategy common in the early commercial stages of biotechnology where top-line growth is the primary focus for investors. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the firm reinvests all available earnings, or rather all available cash flow, back into research and development to fuel growth rather than distributing income to shareholders. Consequently, the overall growth and income profile of Syndax is characterized by aggressive top-line expansion coupled with significant cash outflows, offering investors exposure to potential future drug approvals rather than current income generation.